Combining Doxorubicin and Cis-Platin for Better Cancer Treatment
Author Information
Author(s): N. Kohno, T. Ohnuma, M. Kaneko, J.F. Holland
Primary Institution: Mount Sinai School of Medicine
Hypothesis
The proper sequence of administering Doxorubicin (DXR) and Cis-Platin (DDP) should be DDP first, followed by DXR.
Conclusion
Administering Cis-Platin before Doxorubicin significantly enhances the effectiveness of cancer treatment.
Supporting Evidence
- Simultaneous exposure to DDP and DXR was found to be synergistic.
- DDP followed by DXR resulted in the best cell kill at a 1-hour interval.
- Prior exposure to DDP increased DXR penetration into the tumor spheroid core.
Takeaway
If you give one medicine first, it helps the second medicine work better against cancer cells.
Methodology
The study used multicellular tumor spheroids from a squamous lung carcinoma cell line and assessed cell survival after drug exposure through clonogenic assays.
Limitations
The study was conducted in vitro, which may not fully represent in vivo conditions.
Participant Demographics
PC-10 squamous lung carcinoma cell line was used.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website